ClinicalTrials.gg
CompletedNCT04315025RPUpdated Jun 4, 2020

Safety Issues of Peribulbar Injection of UC-MSC in Patients With Retinitis Pigmentosa

A Phase 1/2 interventional study of Umbilical Cord Mesenchymal Stem Cell (UC-MSC) and Conditioned Medium (CM) in Retinitis Pigmentosa, sponsored by PT. Prodia Stem Cell Indonesia. Completed at 2 sites in Indonesia. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2020-06-04.

Sponsored by PT. Prodia Stem Cell Indonesia · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 5 months after the study started (first participant enrolled Oct 2018, registered Mar 2020).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
18
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The study will perform UC-MSCs and CM transplantation. The first group will be injected by UCMSC+NaCl. the 2nd group will be injected by UC-MSC+CM. the 3rd group will be injected by CM. Each group consists of 6 subjects. all groups will be transplanted via peribulbar route. the dosage of UC-MSC is 1 million cells for each subject. All groups will be observed until 6 months.

Read the detailed description

The eyes which will give the transplant should be given an aseptic and antiseptic technique to prevent the contamination from the inside and outside. Sterile cover attached to other parts of the face except for the eyes. 1.8 ml cell preparations are suspended in physiological NaCl until it reaches a total of 2 ml volume of cell suspension (for UC-MSC + NaCl group). Stem cell suspension will be injected by peribulbar and if the injection was done, patients will be given a quinolone antibiotic. On day 1st and day 7th after therapy, patients will be observed the presence of infection, inflammation, and increasing of eye pressure. On day 7th, day 30th, and day 90th after therapy, patients will do a visual field test, visual acuity test, electroretinography, funduscopy, and Optical Coherence Tomography examination. The observation results will be written in the observation table and analyzed by a statistic. After the data was completed, then make a discussion, conclusion, and suggestion of the study.

02

Conditions studied

  • Retinitis Pigmentosa

Browse trials for

Keywords

  • Allogeneic Mesenchymal Stem Cell
  • Umbilical Cord Mesenchymal Stem Cell
  • Conditioned Medium
  • Allogeneic Umbilical Cord Mesenchymal Stem Cell
03

In context

Retinitis Pigmentosa

278 studies on the registry are indexed under Retinitis Pigmentosa; 72 are open to participants now.

This study's enrollment of 18 is below the median of 27 across 179 interventional studies indexed under Retinitis Pigmentosa.

Browse Retinitis Pigmentosa studies →

Lead sponsor

PT. Prodia Stem Cell Indonesia is the lead sponsor of 16 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Visual field defects at initial examination with Humhprey perimetry are between 25% to 50%
  • Willing to sign as research subjects
  • Willing to do peribulbar injection with mesenchymal stem cells isolated from umbilical cord tissue
  • Willing to do visual field checks with Humphrey's perimetry, vision tests with Snellen boards, Optical Coherrent Tomography (OCT) examinations, electroretinogram examinations and fill out a quality of life questionnaire

Exclusion criteria

Exclusion Criteria:

  • Pregnant or nursing women
  • Positive result of test
  • Have a history of eye tumors
  • In treatment or other drugs that can affect the growth of transplanted stem cells
  • Have another eye disease such as diabetic retinopathy, uveitis, cataract, and glaucoma
  • Do not come to control according to the schedule determined by the researcher (loss to follow up)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
18 participants (actual)

Study arms

  • Active comparator
    Conditioned Medium (CM)

    a total 2 ml volume of Conditioned Medium derived Umbilical Cord Mesenchymal Stem Cell will be injected by peribulbar

    Biological: Conditioned Medium (CM)

  • Active comparator
    UC-MSC + NaCl

    1.8 ml cell preparations are suspended in physiological NaCl until it reaches a total of 2 ml volume of cell suspension. Umbilical Cord Mesenchymal Stem Cell (UC-MSC) suspension will be injected by peribulbar

    Biological: Umbilical Cord Mesenchymal Stem Cell (UC-MSC)

  • Active comparator
    UC-MSC+CM

    1.8 ml cell preparations are suspended in Conditioned Medium (CM) until it reaches total of 2 ml volume of cell suspension. Umbilical Cord Mesenchymal Stem Cell (UC-MSC) + Conditioned Medium (CM) suspension will be injected by peribulbar

    Biological: Umbilical Cord Mesenchymal Stem Cell (UC-MSC) · Biological: Conditioned Medium (CM)

Interventions

06

What researchers measure

Primary outcomes

  1. Visual Acuity Test

    a test to see the sharpness of vision using Snellen Chart which is read at a distance of 6 meters. Normal eye test results are stated in 6/6.

    Time frame: 1 week after injection

  2. Visual Acuity Test

    a test to see the sharpness of vision using Snellen Chart which is read at a distance of 6 meters. Normal eye test results are stated in 6/6.

    Time frame: 1 month after injection

  3. Visual Acuity Test

    a test to see the sharpness of vision using Snellen Chart which is read at a distance of 6 meters. Normal eye test results are stated in 6/6.

    Time frame: 3 months after injection

  4. Visual Field Test

    a test to assess the breadth of views of the lateral, medial, superior and inferior aspects using Humprey's perimetry.

    Time frame: 1 week after injection

  5. Visual Field Test

    a test to assess the breadth of views of the lateral, medial, superior and inferior aspects using Humprey's perimetry.

    Time frame: 1 month after injection

  6. Visual Field Test

    a test to assess the breadth of views of the lateral, medial, superior and inferior aspects using Humprey's perimetry.

    Time frame: 3 months after injection

  7. Funduscopy

    an examination to see and assess the abnormalities and conditions in the ocular fundus using an ophthalmoscope. This examination is carried out by an ophthalmologist.

    Time frame: 1 week after injection

  8. Funduscopy

    an examination to see and assess the abnormalities and conditions in the ocular fundus using an ophthalmoscope. This examination is carried out by an ophthalmologist.

    Time frame: 1 month after injection

  9. Funduscopy

    an examination to see and assess the abnormalities and conditions in the ocular fundus using an ophthalmoscope. This examination is carried out by an ophthalmologist.

    Time frame: 3 months after injection

  10. Electrorectinography

    an examination to provide a picture of objectivity, a quantitative measure of retinal function to monitor the function of stem cells and ganglion cells in the eye. This examination is carried out by a trained ophthalmologist.

    Time frame: 1 week after injection

  11. Electrorectinography

    an examination to provide a picture of objectivity, a quantitative measure of retinal function to monitor the function of stem cells and ganglion cells in the eye. This examination is carried out by a trained ophthalmologist.

    Time frame: 1 month after injection

  12. Electrorectinography

    an examination to provide a picture of objectivity, a quantitative measure of retinal function to monitor the function of stem cells and ganglion cells in the eye. This examination is carried out by a trained ophthalmologist.

    Time frame: 3 months after injection

  13. Optical Coherence Tomography (OCT)

    is a diagnostic test that give the information about posterior segment structure, which is retina and optic nerve papillae so that it can be used to assess macular abnormalities

    Time frame: 1 week after injection

  14. Optical Coherence Tomography (OCT)

    is a diagnostic test that give the information about posterior segment structure, which is retina and optic nerve papillae so that it can be used to assess macular abnormalities

    Time frame: 1 month after injection

  15. Optical Coherence Tomography (OCT)

    is a diagnostic test that give the information about posterior segment structure, which is retina and optic nerve papillae so that it can be used to assess macular abnormalities

    Time frame: 3 months after injection

  16. Angiography

    a process of taking photos of the retina by injecting fluorescent to get a bleeding location on the retina.

    Time frame: 1 week after injection

  17. Angiography

    a process of taking photos of the retina by injecting fluorescent to get a bleeding location on the retina.

    Time frame: 1 month after injection

  18. Angiography

    a process of taking photos of the retina by injecting fluorescent to get a bleeding location on the retina.

    Time frame: 3 months after injection

07

Study locations

2 sites
  • Jakarta Eye Center Hospital
    Jakarta, DKI Jakarta, Indonesia
  • Sardjito Hospital
    Yogyakarta, Special Region 55284, Indonesia
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2018 to primary completion in Jun 2019, 8 months.

Of 28 phase 1/2 interventional studies under Retinitis Pigmentosa, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 92. This study's 8 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 8, 2020
First posted
Mar 19, 2020
StartActual
Oct 7, 2018
Primary completionActual
Jun 20, 2019
CompletionActual
Sep 20, 2019
Last update
Jun 4, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04315025
Lead sponsor
PT. Prodia Stem Cell Indonesia
Responsible party
Sponsor
First posted
Mar 19, 2020
Start date
Oct 7, 2018
Primary completion
Jun 20, 2019
Completion
Sep 20, 2019
Last update
Jun 4, 2020

Study contacts

dr Cosmos O Mangunsong, Sp.M
principal investigator · Gadjah Mada University, Faculty of Medicine
Professor dr. Yohanes W Wirohadidjojo, Sp.KK(K), PhD
study director · Gadjah Mada University, Faculty of Medicine
Bayu W Putera, S.Si, M.Kes
study director · Prodia Stem Cell Indonesia
dr Bayu M Sasongko, Sp.M, PhD
study director · Gadjah Mada University, Faculty of Medicine
dr Melita S Djaja, Sp.M
study chair · Jakarta Eye Center
dr Amyra D Costa
study chair · Jakarta Eye Center
Rima Haifa, B.Sc
study chair · Prodia StemCell Indonesia

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Solizmestrocel

Start the discussion